Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session

22MO - Homologous Recombination Gene Mutations in Uterine Serous Cancer: A Phenotype of the Hereditary Breast and Ovarian Cancer Syndrome?


24 Feb 2023


Mini Oral session


Tumour Site

Endometrial Cancer


Muhammad Danyal Ahsan


Annals of Oncology (2023) 8 (1suppl_1): 100792-100792. 10.1016/esmoop/esmoop100792


M.D. Ahsan1, S. Levi2, E. Webster2, B. Harvey2, E. Cantillo2, E. Chapman-Davis2, K. Holcomb2, M. Frey2

Author affiliations

  • 1 Weill Cornell Medicine, NY 10021 - New York/US
  • 2 Weill Cornell Medicine, New York/US


Login to access the resources on OncologyPRO.

Abstract 22MO


To determine the prevalence of somatic homologous recombination (HR) gene mutations in uterine serous cancer (USC) and compare these with rates among high-grade serous ovarian cancer (HGSOC).


The American Association for Cancer Research’s (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) database version 12.0 was queried via cBioPortal (http://genie.cbioportal.org). This is a publicly available, multi-institutional database of next-generation sequencing genomic profiles of tumor samples. Mutation frequencies for 8 homologous recombination deficiency (HRD) genes are reported and compared between uterine serous cancer (USC) and high-grade serous ovarian cancer (HGSOC) samples using chi-squared or Fisher's exact tests. The threshold used for statistical significance was a two-sided alpha of 0.05.


Table: 22MO

Comparison of mutation frequencies of HR genes between tumor samples from uterine serous cancer and high-grade serous ovarian cancer

Mutation frequency among USC Mutation frequency among HGSOC P-value
BRCA1 12/776, 1.5% 313/3125, 10.0% p<0.001
BRCA2 40/776, 5.2% 218/3125, 7.0% p<0.001
BRIP1 4/752, 0.5% 57/2974, 1.9% p<0.01
CHEK2 6/768, 0.8% 19/3040, 0.6% 0.82
BARD1 12/664, 1.8% 55/2615, 2.1% 0.74
RAD51C 3/671, 0.4% 27/2663, 1.0% 0.25
RAD51D 4/671, 0.6% 24/2658, 0.9% 0.59
PALB2 12/766, 1.6% 37/3045, 1.2% 0.58

Among 844 USC samples, the most prevalent somatic HR gene mutations were BRCA2 (5.2%), BARD1 (1.8%), PALB2 (1.6%) and BRCA1 (1.5%). When compared to 3304 HGSOC samples, higher HR gene mutation frequencies among HGSOC were only found for BRCA1 (10.0% vs 1.5%, p<0.001), BRCA2 (7.0% vs 5.2%, p<0.001) and BRIP1 (1.9% vs 0.5%, p<0.01); however, there was no difference between HGSOC and USC samples in mutation frequencies of BARD1, CHEK2, RAD51C, RAD51D or PALB2.


Genomic profiling of USC tumor samples demonstrates a substantial rate of somatic gene mutations conferring HR deficiency, with rates for most HR gene mutations similar to those found among HGSOC samples. This demonstrates the need for genetically targeted clinical trials of poly-ADP ribose polymerase (PARP) inhibitors in patients with USC, and further research into the germline genetic profile of these patients to establish if this rare uterine cancer could be a phenotype of the hereditary breast and ovarian cancer syndrome.

Legal entity responsible for the study

The authors.


Has not received any funding.


K. Holcomb: Other, Personal, Expert Testimony, Expert Testimony: Johnson & Johnson. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.